Takeda Pharmaceutical (NYSE:TAK) Releases FY 2024 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 3.060-3.060 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Price Performance

NYSE TAK traded up $0.02 during trading on Friday, hitting $13.96. 811,765 shares of the company’s stock were exchanged, compared to its average volume of 1,648,926. The company has a market cap of $44.42 billion, a PE ratio of 24.07, a P/E/G ratio of 0.26 and a beta of 0.54. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. Takeda Pharmaceutical has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The stock’s 50 day moving average price is $14.47 and its two-hundred day moving average price is $13.79.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 9.88%. Research analysts expect that Takeda Pharmaceutical will post 1.58 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.